[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595528":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":26,"studyPopulation":27,"armGroups":22,"interventions":22,"overallOfficials":22,"centralContacts":28,"locations":34,"responsibleParty":51,"collaborators":22,"id":55,"slug":22,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":22,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":22,"enrollmentInfo":62,"targetDuration":22,"studyType":65,"phases":22,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":71,"whyStopped":22,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Harbin Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Major adverse cardiovascular event (MACE)","A major adverse cardiovascular event (MACE) of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke","2 years",[14,16,18,20],{"measure":15,"description":15,"timeFrame":12},"Cardiovascular death",{"measure":17,"description":17,"timeFrame":12},"All-cause death",{"measure":19,"description":19,"timeFrame":12},"Myocardial infarction",{"measure":21,"description":21,"timeFrame":12},"Stroke",null,{"allocation":22,"interventionModel":22,"interventionModelDescription":22,"primaryPurpose":22,"observationalModel":24,"timePerspective":25,"maskingInfo":22},"COHORT","PROSPECTIVE","This is a single-center, observational, prospective cohort study. The primary endpoint is the incidence of MACE. Participants must meet at least two of the following criteria: hypertension, hyperglycemia, hyperlipidemia, or obesity. Baseline data and biological samples will be collected at enrollment, with clinical outcomes monitored for a minimum of two years. The study aims to enroll 10,000 participants aged 45 years and older from Harbin city, located in northeastern China.","The study will enroll 10,000 participants aged 45 and above from Harbin, a city in northeastern China. To be eligible, participants must meet at least two of the following criteria: hypertension, hyperglycemia, hyperlipidemia, or obesity.",[29],{"name":30,"role":31,"phone":32,"phoneExt":22,"email":33},"Haibo Jia, MD","CONTACT","15945685291_","jhb101180@163.com",[35],{"facility":36,"status":22,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"The Second Affiliated Hospital of Harbin Medical University","Harbin","Heilongjiang","150000","China","CN",{"type":43,"coordinates":44},"Point",[45,46],126.65,45.75,{"lat":46,"lon":45},[49],{"name":30,"role":31,"phone":50,"phoneExt":22,"email":33},"15945685291",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Yu Bo","Director, Cardiology Department, the 2nd Affiliated Hospital of Harbin Medical University","100595528",false,"NCT07033624","Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study","Inclusion Criteria:\n\n* 1.Residents of Harbin city, regardless of gender.\n* 2.Meets at least two of the following conditions: diabetes, hypertension, hyperlipidemia, or obesity.\n* 3.No history of cardiovascular or cerebrovascular diseases.\n* 4.Willing to participate in the study and sign the informed consent form\n\nExclusion Criteria:\n\n* 1.History of antibiotic or probiotic treatment within the past month.\n* 2\\. Pregnant women.\n* 3\\. History of autoimmune diseases or malignant tumors; severe heart, liver, or kidney dysfunction; or a history of severe cardiovascular or cerebrovascular diseases.\n* 4\\. Any unstable condition or situation that may jeopardize patient safety or compliance.\n* 5\\. Patients unable to provide informed consent due to physical reasons or unwilling to participate.","ALL","45 Years",{"count":63,"type":64},10000,"ESTIMATED","OBSERVATIONAL","The aim of this prospective cohort study is to collect the multi-omics profile of cardiovascular disease (CVD) high-risk individuals in Harbin, and to discover novel biomarker signatures of major adverse cardiovascular events (MACE) during a minimum 2-year follow-up period.",[68],"Cardiovascular Diseases",[70],"Cardiovascular diseases, microbiome, genomics, metabolism, imaging, risk prediction","NOT_YET_RECRUITING","2025-06-13",{"date":74,"type":75},"2025-06-24","ACTUAL",{"date":77,"type":64},"2025-07-01",{"date":79,"type":64},"2047-07-01",{"name":5,"class":6},1]